Global Blood Therapeutics Inc.
31.49 - 33.76
21.65 - 40.69
Join Discuss about GBT with like-minded investors
goodnight everyone. I will try to sleep soon and will start my trading tomorrow 9am GBT precisely ;)
121 Replies 11 👍 12 🔥
yeah GBT picking up nicely matt
127 Replies 15 👍 9 🔥
GBT looking like fire
66 Replies 12 👍 10 🔥
Next Dividend Date
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
CEO: Ted Love
HQ: 181 Oyster Point Blvd South San Francisco, 94080 California